ReWalk Robotics Ltd. (NASDAQ:LFWD – Get Free Report) Director Michael Swinford purchased 16,907 shares of the stock in a transaction dated Friday, November 22nd. The shares were purchased at an average cost of $1.83 per share, for a total transaction of $30,939.81. Following the completion of the acquisition, the director now directly owns 43,418 shares in the company, valued at approximately $79,454.94. This trade represents a 63.77 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Michael Swinford also recently made the following trade(s):
- On Wednesday, November 20th, Michael Swinford bought 16,471 shares of ReWalk Robotics stock. The stock was purchased at an average cost of $1.84 per share, for a total transaction of $30,306.64.
ReWalk Robotics Price Performance
Shares of NASDAQ:LFWD traded up $0.10 during mid-day trading on Tuesday, reaching $2.17. 7,947 shares of the company traded hands, compared to its average volume of 43,581. ReWalk Robotics Ltd. has a 52 week low of $1.70 and a 52 week high of $9.10. The firm has a market cap of $19.12 million, a PE ratio of -0.83 and a beta of 2.07. The company’s 50 day moving average price is $2.58 and its 200-day moving average price is $3.52.
Hedge Funds Weigh In On ReWalk Robotics
An institutional investor recently bought a new position in ReWalk Robotics stock. Dimensional Fund Advisors LP bought a new position in ReWalk Robotics Ltd. (NASDAQ:LFWD – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned about 0.16% of ReWalk Robotics at the end of the most recent quarter. 26.76% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of ReWalk Robotics in a report on Wednesday, November 13th.
Get Our Latest Stock Analysis on LFWD
About ReWalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.
Recommended Stories
- Five stocks we like better than ReWalk Robotics
- Pros And Cons Of Monthly Dividend Stocks
- 3 Stocks That Authorized $1 Billion Stock Buybacks to Boost Value
- The Significance of Brokerage Rankings in Stock Selection
- Pure Storage’s GenAI Pods and AI Trends Could Spark Recovery
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Is Seaboard Corporation a Thanksgiving Feast for Investors?
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.